Biohaven Appoints Chairman and CFO

Biohaven Pharmaceutical, a biopharma company with a portfolio of late-stage candidates targeting neurological diseases including rare disorders, has appointed Vlad Coric, MD, Chairman of the Board of Directors following the retirement of Declan Doogan, MD, effective immediately. The company also appointed Matthew Buten as Chief Financial Officer, following the retirement of CFO James Engelhart. Both Dr. Doogan and Mr. Engelhart will continue to advise the company after their retirement to ensure a smooth transition. Current Director Michael Heffernan has been appointed Lead Independent Director, effective immediately.

As a former managing director of Foresite Capital, Mr. Buten brings more than 20 years of experience in healthcare investing as well as 15 plus years as an advisor in investment banking and strategic structuring of deals for both small and large capitalization companies. Previously, Mr. Buten served as a healthcare portfolio manager at Catapult/Millennium Partners. 

Vlad Coric, MD, Chairman and Chief Executive Officer of Biohaven said, "We are excited to welcome Matt to our executive leadership team as CFO as he brings deep expertise in healthcare investment banking, venture capital, corporate strategy and private equity to Biohaven. We also extend our immense gratitude to Declan and Jim for their strategy and leadership since the Company's inception that contributed to the success of Biohaven."
Incoming CFO Matt Buten ssaid, "Biohaven has established itself as a market leading commercial-stage pharmaceutical company with the successful launch of Nurtec® ODT and is at the beginning of its growth potential as a company. I am excited to join Vlad and the entire team to help advance novel Therapeutics to patients. Biohaven is poised to transform the field of neurologic treatments and I am looking forward to contribute to its future success."